Elevation of miR-221 and -222 in the internal mammary arteries of diabetic subjects and normalization with metformin

Molecular and Cellular Endocrinology

Volumn 374, Issue 1-2, 2013, Pages 125-129

  Coleman, Chasity B ^a,c   Lightell, Daniel J ^a,b   Moss, Stephanie C ^a   Bates, Michael ^a   Parrino, Patrick E ^a   Woods, T Cooper ^a,b,d  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Internal mammary artery; Metformin; MiR 221 222; Vascular smooth muscle cell

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLITAZONE DERIVATIVE; INSULIN; MESSENGER RNA; METFORMIN; MICRORNA 221; MICRORNA 222; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DOSE RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTERNAL MAMMARY ARTERY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

AGED; BIOPSY; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MAMMARY ARTERIES; METFORMIN; MICRORNAS; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PRIMARY CELL CULTURE;

EID: 84878700567     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.04.019     Document Type: Article

References (20)

1. Bonora E., Tessari R., Micciolo R., Zenere M., Targher G., Padovani R., Falezza G., Muggeo M. Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Relationship with insulin resistance. Diabetes Care 1997, 20:627-631.
2. Lightell D.J., Moss S.C., Woods T.C. Loss of canonical insulin signaling accelerates vascular smooth muscle cell proliferation and migration through changes in p27Kip1 regulation. Endocrinology 2011, 152:651-658.
3. Ahanchi S.S., Varu V.N., Tsihlis N.D., Martinez J., Pearce C.G., Kapadia M.R., Jiang Q., Saavedra J.E., Keefer L.K., Hrabie J.A., Kibbe M.R. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2388-H2398.
4. Wang C.C., Gurevich I., Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 2003, 52:2562-2569.
5. Nakashima Y., Fujii H., Sumiyoshi S., Wight T.N., Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1159-1165.
6. Liu X., Cheng Y., Yang J., Xu L., Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J. Mol. Cell. Cardiol. 2012, 52:245-255.
7. Liu X., Cheng Y., Zhang S., Lin Y., Yang J., Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res. 2009, 104:476-487.
8. Davis B.N., Hilyard A.C., Nguyen P.H., Lagna G., Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J. Biol. Chem. 2009, 284:3728-3738.
9. Moss S.C., Bates M., Parrino P.E., Woods T.C. Isolation of endothelial cells and vascular smooth muscle cells from internal mammary artery tissue. Ochsner J. 2007, 7:133-136.
10. Moss S.C., Lightell D.J., Marx S.O., Marks A.R., Woods T.C. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J. Biol. Chem. 2010, 285:11991-11997.
11. Herrera B.M., Lockstone H.E., Taylor J.M., Ria M., Barrett A., Collins S., Kaisaki P., Argoud K., Fernandez C., Travers M.E., Grew J.P., Randall J.C., Gloyn A.L., Gauguier D., McCarthy M.I., Lindgren C.M. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010, 53:1099-1109.
12. Li Y., Song Y.H., Li F., Yang T., Lu Y.W., Geng Y.J. MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem. Biophys. Res. Commun. 2009, 381:81-83.
13. Zhao C., Dong J., Jiang T., Shi Z., Yu B., Zhu Y., Chen D., Xu J., Huo R., Dai J., Xia Y., Pan S., Hu Z., Sha J. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One 2011, 6:e23925.
14. Ortega F.J., Mercader J.M., Catalan V., Moreno-Navarrete J.M., Pueyo N., Sabater M., Gomez-Ambrosi J., Anglada R., Fernandez-Formoso J.A., Ricart W., Fruhbeck G., Fernandez-Real J.M. Targeting the circulating MicroRNA signature of obesity. Clin. Chem. 2013, 59:781-792.
15. Diez-Juan A., Andres V. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. Faseb J. 2001, 15:1989-1995.
16. Akyurek L.M., Boehm M., Olive M., Zhou A.X., San H., Nabel E.G. Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun. 2010, 396:359-363.
17. Shahzad K., Thati M., Wang H., Kashif M., Wolter J., Ranjan S., He T., Zhou Q., Blessing E., Bierhaus A., Nawroth P.P., Isermann B. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis 2011, 219:74-83.
18. Li L., Mamputu J.C., Wiernsperger N., Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005, 54:2227-2234.
19. Isoda K., Young J.L., Zirlik A., MacFarlane L.A., Tsuboi N., Gerdes N., Schonbeck U., Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:611-617.
20. Katakami N., Yamasaki Y., Hayaishi-Okano R., Ohtoshi K., Kaneto H., Matsuhisa M., Kosugi K., Hori M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004, 47:1906-1913.